Systemic Management Of Malignant Meningiomas: A Comparative Survival And Molecular Marker Analysis Between Octreotide In Combination With Everolimus And Sunitinib

PurposeTo compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas.Methods31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFR beta and VEGFR2, their expression was correlated with outcomes.ResultsTwenty-two patients (72%) were female with a median age of 55 years (SD +/- 15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95% CI 28.5-42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95% CI 9.2-21.1) and 9.1 months (95% CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO -> Su -> Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su -> EO -> Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFR beta and negative VEGFR2 expression were associated with longer survival both in OS and PFS.ConclusionSunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFR beta expression are associated with better outcomes.